Neutral LPAR1 Antagonists for the Treatment of Idiopathic Pulmonary Fibrosis
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.5c00263 ↗Kurz gefasst
Kommentar in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Xiaojing Wang. Beteiligte Einrichtung: Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States. Hauptthemen laut MEDLINE: Idiopathic Pulmonary Fibrosis, Receptors, Lysophosphatidic Acid. Die Arbeit nennt 12 Literaturangaben.
Abstract (Originalsprache)
Despite significant advancements in the treatment options for idiopathic pulmonary fibrosis (IPF), the disease remains aggressive and incurable. This viewpoint summarizes the discovery of a neutral, potent, and selective lysophosphatidic acid receptor 1 antagonist for the treatment of IPF. The lead optimization without the cocrystal structure guidance is worth it to highlight.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
ORCID-Profile: Xiaojing Wang
Zitieren
APA
Wang, X. (2025). Neutral LPAR1 Antagonists for the Treatment of Idiopathic Pulmonary Fibrosis. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c00263
Vancouver
Wang X. Neutral LPAR1 Antagonists for the Treatment of Idiopathic Pulmonary Fibrosis. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c00263
BibTeX
@article{Wang2025,
author = {Wang, Xiaojing},
title = {Neutral LPAR1 Antagonists for the Treatment of Idiopathic Pulmonary Fibrosis},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.5c00263}
}
EUVIMED